Why the study?
Does cardiac resynchronisation therapy improve prognosis and symptoms in patients with chronic heart failure, left ventricular systolic dysfunction, and conduction delay?
Does cardiac resynchronisation therapy improve prognosis and symptoms in patients with chronic heart failure, left ventricular systolic dysfunction, and conduction delay?
Cardiac resynchronisation therapy is established as a routine therapy with clear mortality benefits for patients with chronic heart failure, LVEF ≤35%, and QRS >120 ms.
No takes yet. Share an insight, caveat, or question.
Supports CRT as standard for eligible HF patients; leaves open optimization of selection amid newer therapies.
Cubbon et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: